PCVX

Vaxcyte, Inc.

58.51

1.19+2.08%

After Hours: 58.51 0.00 0.00%17:09 02/20 EST

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE57.19/57.32

TODAY RANGE55.68-58.74

VOL1.09M

MARKET CAP8.25B

52 WEEK RANGE27.66-85.22

AVG VOL (3M)1.40M

% TURNOVER0.78%

TURNOVER--

P/E (TTM)-12.0936

% RANGE5.26%

EPS(TTM)-4.8381

P/E(FORWARD)-10.6092

P/B2.630

BVPS22.25

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP8.18B

SHARES OUTSTANDING141.03M

NEXT EARNINGS02/23-02/27

FREE FLOAT139.85M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·1d ago
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors
Simply Wall St·3d ago
A Look At Vaxcyte (PCVX) Valuation After OPUS-3 Phase 3 Dosing Milestone
NASDAQ·4d ago
XBI, ROIV, HALO, PCVX: Large Inflows Detected at ETF
Simply Wall St·6d ago
OPUS-3 Launch and Broad VAX-31 Program Could Be A Game Changer For Vaxcyte (PCVX)
TipRanks·02/13 12:10
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vaxcyte (PCVX), Avita Medical (RCEL) and Medtronic (MDT)
TipRanks·02/11 21:30
Vaxcyte doses first participants in OPUS-3 trial
Benzinga·02/11 21:28
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31; Company Expects To Report Topline Data From OPUS-3 Trial And OPUS-2 Phase 3 Trial Evaluating Concomitant Administration Of VAX-31 And A Seasonal Influenza Vaccine In First Half Of 2027
Reuters·02/11 21:05
Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults
Reuters·02/11 21:05
VAXCYTE INC - TOPLINE DATA FROM OPUS-3 AND OPUS-2 TRIALS EXPECTED IN H1 2027
Reuters·02/10 21:05
Vaxcyte Inc. to report financial results and provide business update
Simply Wall St·02/08 05:03
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline
NASDAQ·02/06 15:50
XBI, PCVX, MIRM, RVMD: Large Outflows Detected at ETF
Reuters·02/05 21:06
Vaxcyte to Present at Guggenheim Emerging Outlook Biotech Summit
TipRanks·02/02 21:43
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
Reuters·02/02 21:02
Vaxcyte nimmt durch Aktienemission 600 Millionen Dollar ein

Same Industry

Name/Symbol

Change%

Price

Vaxcyte, Inc.

PCVX

+2.08%

58.51

Regeneron Pharmaceuticals

REGN

-0.23%

779.67

GridAI Tech

GRDX

-5.15%

2.58

BIONTECH

BNTX

-0.25%

110.15

United Therapeutics Corp.

UTHR

-1.48%

473.42

Vertex Pharmaceuticals Inc

VRTX

+1.63%

476.90

Siga Technologie

SIGA

-0.30%

6.75

Moderna

MRNA

+0.34%

49.87

Charles Riv Labs Intl Inc

CRL

+2.85%

168.92

Medpace Holdings

MEDP

+1.64%

453.77

Talphera Inc

TLPH

-3.87%

0.7766

ICON PLC

ICLR

+1.31%

99.70

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-2.21%

165.62

MOLECULAR PARTNERS AG

MOLN

0.00%

5.00

Arcturus Therape

ARCT

-3.76%

7.67

Gilead Sciences Inc

GILD

+0.19%

151.40

PRA Health

PRAH

165.21

Incyte Corp

INCY

-0.40%

101.32

Aptevo Therapeutics Inc

APVO

-4.58%

6.66

Biospecifics

BSTC

+0.15%

88.53